InflaRx on large white.jpg
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
10 janv. 2022 07h30 HE | InflaRx N.V.
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response
28 sept. 2021 11h17 HE | BioAegis Therapeutics
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype. NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) --...
22157.jpg
Ulcerative Colitis Clinical Landscape Report 2021: Pipeline Holds Multiple Novel Prospects in Terms of Distinct Mechanisms of Action and Biologics
12 juil. 2021 05h33 HE | Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Ulcerative Colitis" report has been added to ResearchAndMarkets.com's offering. UC typically presents with bloody diarrhea, which may...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
29 juin 2021 13h58 HE | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
logo.png
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
24 juin 2021 08h05 HE | Corbus Pharmaceuticals Holdings, Inc.
Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
08 avr. 2021 18h58 HE | BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression.  Gelsolin is non-immunosuppressive unlike current treatments to quell...
Silencil Reviews: Negative Side Effects or Real Tinnitus Aid
04 avr. 2021 06h00 HE | Marketing By Kevin
Chicago, IL, April 04, 2021 (GLOBE NEWSWIRE) -- Silencil is a daily supplement for tinnitus to alleviate the ringing in the ears that is caused by inflammation in the brain. The formula, found...
180_LS_logo.png
180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters
25 mars 2021 08h30 HE | 180 Life Sciences Corp.
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
15 mars 2021 11h12 HE | BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
thumbnail_Pan-Biome-logo.png
Pan-Biome Pharmaceuticals, Inc reports positive results in preclinical trial of Inflammatory Bowel Disease: oral drug shows strong effect in modulating the gut microbiome
24 févr. 2021 10h00 HE | Pan-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pan-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on chronic inflammatory and autoimmune...